Trial reportActa ophthalmologica2025
Myopia control with orthokeratology lenses. A 3-year follow-up study including a cross-over design: Clinical study Of Near-sightedness; TReatment with Orthokeratology Lenses 2 (CONTROL2 study).
Trial report in Acta ophthalmologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effectiveness of orthokeratology in controlling myopia in adolescents aged 6-18 years: a systematic review and meta-analysis.International ophthalmology · 2026Pooled it
- Defocus incorporated multiple segment spectacle lenses versus orthokeratology lenses for myopia control: a non-inferiority randomised clinical trial.BMC ophthalmology · 2026Trial
- Myopia control with orthokeratology lenses. A 3-year follow-up study including a cross-over design: Clinical study Of Near-sightedness; TReatment with Orthokeratology Lenses 2 (CONTROL2 study).Acta ophthalmologica · 2025Trial
- Compliance with orthokeratology lens wear: a systematic review and meta-analysis.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Review
- Changes in choroidal and retinal thickness 6 months before and during 18 months of orthokeratology lens treatment in myopic children.Acta ophthalmologica · 2026Article
- Clinical Safety and Performance of Ultra-High Dk Tisilfocon A Orthokeratology Lenses: A Prospective Multicenter Study.Life (Basel, Switzerland) · 2026Article
- Real-Life Orthokeratology for Myopia Control in Hungarian Children: A Five-Year Study of Axial Length Changes.Life (Basel, Switzerland) · 2026Article
- Article
- Association Between Pupil Area and the Efficacy of Peripheral Defocus Spectacle Lenses in Myopia Control.Translational vision science & technology · 2026Article
- Association between first-year axial elongation and 10-year myopia progression in children wearing orthokeratology lenses: a ten-year longitudinal study.Frontiers in cell and developmental biology · 2026Article
- Comparative Evaluation of the Efficacy, Safety, and Corneal Dynamics of Overnight Orthokeratology in Teenagers and Adults With Myopia: A Prospective, Open-Label Study in Taiwan.Journal of ophthalmology · 2026Article
- Axial length changes and baseline predictors over five years in children treated with orthokeratology lenses: a retrospective cohort study.Frontiers in bioengineering and biotechnology · 2026Article
- Orthokeratology for myopia control: a three-year longitudinal study on axial length modulation influenced by baseline age and spherical equivalent.BMC ophthalmology · 2025Article
- Slowing Myopia Progression in Adolescents Using Orthokeratology: A Retrospective Chart Review.Cureus · 2025Article
- Analysis of axial shortening induced by orthokeratology lenses and its mechanical mechanisms.PloS one · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
purposeThe purpose of this study is to investigate 3-year efficacy of orthokeratology lenses (OKL) in controlling axial length progression in myopic Scandinavian children. Through a cross-over design of the control group to compare the treatment efficacy in younger versus older children, with the latter having higher cycloplegic spherical refractive error (cSEQ) at treatment initiation. Further, the study aimed to evaluate the safety of the treatment.
methodsThis was a continuation of the randomized controlled study Clinical study Of Near-sightedness; TReatment with Orthokeratology Lenses (CONTROL study) in which the follow-up period of the original intervention group, that received OKL, was extended from 18 months to 36 months. Meanwhile, the original control group was crossed-over to OKL after the 18-month follow-up visit and treated for 18 months. Biometry was measured using Lenstar LS900, and contact lens complications were graded according to Efron Grading Scale for Contact Lens Complications (Efron score). Mixed models were used for statistical analysis.
resultsNineteen subjects in the OKL group and 28 in the control group completed the CONTROL study. Hereof, 17 and 24 subjects from the OKL group and control group, respectively, agreed to participate in the CONTROL2 study. In the OKL continue group, the treatment efficacy did not decline during the 3-year study period (p-values for follow-up visits were all ≥0.82). There was no statistically significant difference between treatment efficacy when OKL treatment was initiated in younger versus older children (p-value ≥0.14 for all follow-up visits). Low-grade corneal staining was seen in several subjects at some point during the study, but here were no treatment-requiring or sight-threatening adverse events during the study period.
conclusionThe efficacy of myopia control by OKL was stable during 3 years of treatment. Similar treatment efficacies were found regardless of the age at treatment initiation. No severe adverse events occurred during the study period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.